SARS CoV 2 News and Research

RSS

Breakthrough in antigen recognition: TRACeR-I enhances immune targeting

Researchers describe TRACeR-I, a protein platform that can be used to engineer immune responses.

19 Dec 2024

New long COVID index highlights five symptom subtypes

Researchers provide a detailed report of the updated 2024 long COVID research index.

19 Dec 2024

Long COVID affects 8.4% of U.S. adults, with income and geography shaping impact

Long COVID affects 8.4% of U.S. adults, with significant disparities based on sex, income, and geography, limiting daily activities for many.

17 Dec 2024

Breakthrough microchip technology enables multi-disease detection

In a world grappling with a multitude of health threats - ranging from fast-spreading viruses to chronic diseases and drug-resistant bacteria - the need for quick, reliable, and easy-to-use home diagnostic tests has never been greater. Imagine a future where these tests can be done anywhere, by anyone, using a device as small and portable as your smartwatch.

16 Dec 2024

Gut microbiome during acute infection predicts risk of long COVID

The study identifies gut microbiome signatures during acute SARS-CoV-2 infection as predictors of long COVID, enhancing understanding of symptom variability.

16 Dec 2024

A genetic variant modulates interferon signaling and disease risk

For years, scientists have looked to a critical piece of immune system machinery - known as the interferon pathway - for answers. There, when our cells sense an infection, they release a protein known as interferon, which warns other cells to fight the virus.

13 Dec 2024

Researchers classify post-COVID subtypes and uncover vaccination’s protective role

Researchers identify four distinct post-COVID subtypes, reveal key risk factors, and emphasize the protective role of vaccination in mitigating long-term impacts.

12 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Psilocybin helps reduce depression in clinicians amid COVID-19 crisis

Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021.

5 Dec 2024

Long-COVID lingers in children

A 24-month study reveals that 7.2% of children consistently experience long-COVID symptoms, with tiredness, sleep issues, and headaches most commonly reported, highlighting the need for targeted interventions.

5 Dec 2024

New research sheds light on how monkeys avoid hepatitis B infection

Hepatitis B virus (HBV) infection is a leading cause of chronic liver diseases, that spreads among individuals through blood or body fluids.

4 Dec 2024

Long Covid in teenagers shows significant improvement within two years

Most young people who were confirmed to have long Covid three months after a positive PCR test had recovered within 24 months, finds a new study led by UCL researchers.

4 Dec 2024

SARS-CoV-2 spike protein found lingering in brain regions

Researchers find that SARS-CoV-2 spike protein persists in the skull-meninges-brain axis, driving neuroinflammation, neurodegeneration, and heightened vulnerability to brain injuries.

3 Dec 2024

Polypurine hairpins found to effectively halt SARS-CoV-2 replication

A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting the proliferation of the SARS-CoV-2 virus that causes COVID-19.

3 Dec 2024

Inflammation and organ damage in severe COVID-19 tied to mitochondrial dysfunction

Severe COVID-19 arises in part from the SARS-CoV-2 virus's impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine, Johns Hopkins Medicine, Children's Hospital of Philadelphia, and the University of Pittsburgh School of Medicine, along with other members of the COVID-19 International Research Team.

3 Dec 2024

Study reveals pathways behind organ damage in severe COVID-19

New research published in the journal Proceedings of the National Academy of Sciences sheds light on the pathways that drive organ damage and death in severe COVID-19 and helps explain why survivors of the disease can experience long-term complications.

2 Dec 2024